[
  {
    "ts": null,
    "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q4 2024 Update",
    "summary": "GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value assets. See more here.",
    "url": "https://finnhub.io/api/news?id=7fee116fab786340e0e08cc4d8e405c129a8999c0cd921f1dac302c5b6a50dcf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739486426,
      "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q4 2024 Update",
      "id": 132709947,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GMO's portfolio update highlights key stock adjustments and forecasts a promising 9.6% return for International Deep Value assets. See more here.",
      "url": "https://finnhub.io/api/news?id=7fee116fab786340e0e08cc4d8e405c129a8999c0cd921f1dac302c5b6a50dcf"
    }
  },
  {
    "ts": null,
    "headline": "Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD",
    "summary": "Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 2025. Read more on GOSS stock here.",
    "url": "https://finnhub.io/api/news?id=e02168ceb6b26e3024611920613628fc7cccb736e28097b91701b723059ad1a2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739475722,
      "headline": "Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD",
      "id": 132709374,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173913540/image_173913540.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 2025. Read more on GOSS stock here.",
      "url": "https://finnhub.io/api/news?id=e02168ceb6b26e3024611920613628fc7cccb736e28097b91701b723059ad1a2"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=2f9c108067ac315b3bb627cc46ce5592fc69578ec2d2e72c765151a7fac25ede",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739464380,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "id": 132721151,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=2f9c108067ac315b3bb627cc46ce5592fc69578ec2d2e72c765151a7fac25ede"
    }
  }
]